Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children (TAPPS)

August 1, 2018 updated by: Camille JUNG
Single-center prospective study to assess the clinical course of group A streptococcal blistering distal dactylitis in children after antibiotic treatment.

Study Overview

Detailed Description

Blistering distal dactylitis are very common in children. About 60% are caused by Staphylococcus aureus and some are caused by Group A Streptococcus (GAS) or Streptococcus pyogenes. While these forms have been known for fifty years, few publications are interested in it. Some studies have confirmed that a single antibiotic treatment against the SGA allows the healing of these dactylitis but few surgical teams have adopted this strategy. As all streptococcal infections, they face the risk of acute complications (septicemia, streptococcal toxic shock, etc.) or late (post-streptococcal glomerulonephritis, acute rheumatic fever, etc.). The involvement of the SGA in these dactylitis is easy to demonstrate through the use of rapid GAS test already widely used in other GAS infections (tonsillitis, scarlet fever, streptococcal perianal infections).

This study aims to assess the clinical course of positive GAS test blistering distal dactylitis in children after antibiotic treatment.

Study Type

Interventional

Enrollment (Actual)

177

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Créteil, France, 94000
        • CHI Creteil

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 16 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children 0-18 years
  • Distal blistering dactylitis collected or not collected
  • Positive rapid Group A Streptococcus test
  • Informed consent signed by the parents

Exclusion Criteria:

  • Subungual or pulp Whitlow
  • Children not affiliated to the social security scheme
  • Refusal by the parents to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Positive rapid Group A Streptococcus (GAS) test
In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy

If TDR positive, the child will be treated with antibiotics alone:

  • Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins
  • Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months.
Active Comparator: Negative rapid GAS test
If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
Usual care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate healed blistering distal dactylitis with positive GAS test after 10 days of antibiotherapy directed against streptococcus pyogenes
Time Frame: 10 days
The main objective of this study is to evaluate the effectiveness of antibiotic treatment only if paronychia subungual child collected or not collected with a in distal blistering dactylitis with positive GAS test
10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of distal blistering dactylitis with positive GAS test in children
Time Frame: 18 months
18 months
Frequency of collected distal blistering dactylitis with positive GAS test in children
Time Frame: 18 months
18 months
Frequency of germs involved in distal blistering dactylitis after pus culture in children
Time Frame: 18 months
18 months
Sensitivity of GAS test compared to pus culture
Time Frame: 18 months
Describe the sensitivity of GAS test in distal blistering dactylitis according to different age groups.
18 months
Specificity of GAS test compared to pus culture
Time Frame: 18 months
Describe the specificity of GAS test in distal blistering dactylitis according to different age groups.
18 months
Correlation between GAS test and pus culture in different age groups
Time Frame: 18 months
18 months
Number of General anesthesia avoided by use of antibiotics treatment instead of surgical procedure in case of collected distal blistering dactylitis
Time Frame: 18 months
18 months
Number of surgical procedures avoided by use of antibiotics treatment instead of surgical procedure in case of collected distal blistering dactylitis
Time Frame: 18 months
18 months
Comparison between the cost of antibiotics versus surgical or local treatments of positive GAS test distal blistering dactylitis in children
Time Frame: 18 months
Evaluate the medical and economic impact of the single antibiotic treatment of distal blistering dactylitis with positive GAS test
18 months
Rate of healed collected distal blistering dactylitis with positive GAS test after antibiotic treatment
Time Frame: 18 months
18 months
Number of Nail dystrophy at 3 months of follow-up
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Camille Jung, MD, PhD, CHIC Créteil

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (Actual)

January 1, 2018

Study Completion (Actual)

March 1, 2018

Study Registration Dates

First Submitted

November 25, 2015

First Submitted That Met QC Criteria

December 4, 2015

First Posted (Estimate)

December 9, 2015

Study Record Updates

Last Update Posted (Actual)

August 2, 2018

Last Update Submitted That Met QC Criteria

August 1, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blistering Distal Dactylitis

Clinical Trials on Positive rapid GAS test

3
Subscribe